Aug 8 (Reuters) - Mesoblast Ltd
- Phase 2 trial of mesoblast cell therapy shows dose-related clinical benefit in patients with biologic refractory rheumatoid arthritis
- Intends to enter into a strategic partnership to advance phase 3 development of allogeneic mpcs for biologic refractory ra
- A single intravenous infusion of proprietary allogeneic mpc product candidate, mpc-300-iv, was well tolerated
(([email protected];))
Aug 8 (Reuters) - Mesoblast Ltd Phase 2 trial of mesoblast cell...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 274918 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 974 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |